Living‐related liver transplantation for patients with fulminant and subfulminant hepatic failure

Shiro Miwa, Yasuhiko Hashikura, Atsuyoshi Mita, Tatsuya Kubota, Hisanao Chisuwa, Yuichi Nakazawa, Toshihiko Ikegami, Masaru Terada, Shinichi Miyagawa, Seiji Kawasaki – 30 December 2003 – The prognosis for patients with fulminant (FHF) or subfulminant hepatic failure (SFHF) has improved since the introduction of liver transplantation. However, the death rate of patients awaiting liver transplantation is high, possibly because of the difficulty in obtaining grafts in a timely manner, given the relative shortage of cadaveric donors.

Phase I and Phase II drug‐metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium

Fatima Lakehal, Dominique Wendum, Véronique Barbu, Laurent Becquemont, Raoul Poupon, Pierre Balladur, Laurent Hannoun, François Ballet, Philippe H. Beaune, Chantal Housset – 30 December 2003 – Tissue expression of drug‐metabolizing enzymes influences susceptibility to drugs and carcinogens. Because the biliary epithelium, exposed to bile‐borne chemicals, may give rise to drug‐induced cholangiopathies and to cholangiocarcinomas, we determined the pattern of expression of drug‐metabolizing enzymes in this epithelium.

Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma

Michiyo Higashi, Suguru Yonezawa, Jenny J. L. Ho, Sadao Tanaka, Tatsuro Irimura, Young S. Kim, Eiichi Sato – 30 December 2003 – Our previous immunohistochemical study on intrahepatic bile duct tumors showed that invasive cholangiocarcinoma (ICC) with a poor outcome expressed MUC1 mucin but was negative for MUC2 mucin, whereas bile duct cystadenocarcinoma (BDCC) with a favorable outcome was MUC1 negative and MUC2 positive. In the present study, ICC was further subdivided into 2 subtypes: intraductal growth type and/or periductal infiltrating type (ICC‐IP) and mass forming type (ICC‐M).

New ways of interfering with HCV replication

Peter Hasselblatt, Hubert E. Blum, Wolf‐Bernhard Offensperger – 30 December 2003 – RNA interference is a cellular process of gene silencing in which small duplexes of RNA specifically target a homologous sequence for cleavage by cellular ribonucleases. The introduction of approximately 22‐nt small interfering RNAs (siRNAs) into mammalian cells can specifically silence cellular mRNAs without induction of the nonspecific IFN responses that are activated by longer RNA duplexes.

Subscribe to